FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS




FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS

WEST PALM BEACH, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces Chief Executive Officer Seamus Lagan has provided the following Year-End Review to shareholders:

FOXO Shareholders:

As we rapidly approach year-end, I wanted to reach out to our shareholders to review key milestones of 2025 and preview our go-forward operating and growth strategy. Much of the foundation of the “new” FOXO was created in mid-2024 when the Company acquired both Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. (including its principal subsidiary, Scott County Community Hospital, Inc.). More recently, we expanded our portfolio of healthcare-related businesses through the acquisition of Vector BioSource, Inc.

Myrtle Recovery Centers

Since opening its doors in August 2023, Myrtle’s first location in Oneida, Tennessee has positioned itself as a leading provider of residential and medically supervised withdrawal treatment services for substance use disorders in greater Tennessee. Key aspects of the business include:

• Has served patients from 63 of 95 counties in Tennessee since opening
• Current average daily census of 28 (93% occupancy) compared to average daily census of 7.4 for 2024 (25% occupancy)
• Patient treatment mix is approximately 85% residential treatment services and 15% medically supervised withdrawal services
• Projected patient admissions of 550 for 2025 compared to 195 patient admissions in 2024
• Received numerous local and statewide accolades and has received awards for its community outreach and care model
• Been awarded funding through the State of Tennessee Opioid Abatement Fund for treatment of uninsured patients in Scott County, Tennessee
• Working with software developers on a mobile application called “Evana” that seeks to connect Myrtle’s post-discharge patient population with Myrtle care professionals with the goal of monitoring and meeting patient after-care needs. Myrtle expects the application will provide improved patient care and satisfaction after discharge, aid in development of a strong alumni support system as well as increase the overall awareness of Myrtle capabilities in the communities it serves.

With its Oneida facility consistently at capacity and having excess referrals, Myrtle is actively considering other locations to replicate its operating model.

Rennova Community Health (including Scott County Community Hospital)

Scott County Community Hospital, known as Big South Fork Medical Center, is FOXO’s flagship acute care hospital (designated as a Critical Access Hospital) serving Scott County, Tennessee and surrounding communities. The facility offers inpatient (including swing bed) services and outpatient and emergency room services alongside a range of ancillary services such as lab, radiology, pharmacy and respiratory services. Hospital profile:

• Projected to see over 7,000 ER patients in 2025 in addition to over 3,500 outpatient visits and 300 inpatient stays
• Recently added swing bed (inpatient) and wound care (inpatient and outpatient) services
• In-network with all major payors (including Medicare Advantage plans and Tennessee Medicaid managed care plans)

Vector BioSource

We believe our most recent acquisition of Vector BioSource, Inc. (“Vector”) establishes FOXO as a growing player in the pharmaceutical services sector. Vector sources biospecimens (blood, urine) and sells such biospecimens to the biotechnology and pharmaceutical research sectors both in the US and abroad. We expect Vector to generate approximately $1 million of net revenues for 2025 and expect significant growth of the business as we invest capital to build infrastructure, expand markets and secure propriety sources of supply. Moreover, we see significant additional acquisition opportunities in this sector.

Corporate and Growth Outlook

From a corporate perspective, we had an active year where several legacy liabilities were settled for cash or more often with FOXO preferred stock. In addition, we both strengthened and streamlined our corporate management team. Our financials demonstrate:

• Reported net revenues of approximately $12 million for the nine months ended September 30, 2025 and expect to exceed $15 million in net revenues for the full year ended December 31, 2025
• Strengthened equity—equity increased from $5.3 million at December 31, 2024 to $20.2 million at September 30, 2025
• Reduced debt from $10.2 million at December 31, 2024, to $7.1 million at September 30, 2025
• Settled in full the $2.3 million legacy liability to Smithline
• Restructured approximately $3.5 million of legacy PIK note debt to preferred stock

We remain optimistic in our operating subsidiaries and are looking intently at augmenting organic growth with acquisitions. In connection with the Company’s acquisition strategy, the Company formed a wholly owned subsidiary, FOXO Acquisition Corporation (“FAC”), that intends to serve as vehicle to make acquisitions and created a new series of preferred stock designated as Series E Cumulative Redeemable Secured Preferred Stock (“Series E Preferred Stock”). The Series E Preferred Stock is not convertible to common stock, is secured by the equity of FAC, has a 2.5% per annum cash dividend and a 5% per annum common stock dividend. Our most recent acquisition, Vector BioSource, Inc., was acquired using the FAC subsidiary and a portion of the acquisition consideration was in the form of Series E Preferred Stock. We intend to list our Series E Preferred Stock with its own trading symbol; however, an eventual listing is not a certainty.

After losing the NYSE American listing of our common stock in the third quarter of 2025 because our minimum share price did not meet the continued listing requirements for NYSE American, we continue to consider options to uplist our common stock to NYSE American or another recognized stock exchange; however, there is no certainty of an eventual uplist. We hope this can be achieved in 2026.

Sincerely,

Seamus Lagan
Chief Executive Officer

About FOXO Technologies Inc. (“FOXO”)

FOXO owns and operates four key subsidiaries.

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for medically supervised withdrawal treatment and residential treatment and outpatient services for MAT and OBOT programs.

Vector BioSource, Inc. is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries.

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains forward-looking statements that include words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions, are forward-looking statements. These statements are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Sebastien Sainsbury
ssainsbury@foxotechnologies.com
(561) 485-0151

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference




Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.

Presentation Details
Date: Monday, January 12, 2026
Time: 3:45pm PST
Webcast Link

The webcast will be available under the Investors section on the Company’s website, www.catalystpharma.com, and a replay will be available for at least 30 days.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

CONTACT: Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com

Media Contact
David Schull or Olipriya Das, Russo Partners
(858) 717-2310, (646) 942-5588
david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com

Big Nova Gives $3 Million to Advance NMDP’s Mission and Help More Patients Receive Blood Stem Cell Transplants




Big Nova Gives $3 Million to Advance NMDP’s Mission and Help More Patients Receive Blood Stem Cell Transplants

Family donations over a decade inspired by loved one’s life-saving transplant helped NMDP surpass $100 million campaign goal

MINNEAPOLIS and ORLANDO, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — NMDP^SM announced today that Big Nova has made a transformational $3 million philanthropic gift that will support thousands of patients receiving life-saving cell therapy from selfless blood stem cell donors. This generous gift propelled NMDP to surpass its ambitious $100 million comprehensive campaign goal, representing a historic achievement that will advance the organization’s mission.

Big Nova’s recent donation will expand access to patient and donor assistance programs, helping more patients overcome the financial barriers associated with transplant and ensuring more donors can say “yes” when called. The gift is expected to have far-reaching impact, supporting thousands of patients and donors navigating the process of receiving or donating blood stem cells to treat more than 75 different blood cancers like leukemia or blood disorders like sickle cell disease.

“Our family knows the hope NMDP brings because we’ve lived it. We felt our worlds turn upside down when a loved one was diagnosed with leukemia, and when an unrelated donor stepped forward to offer her a chance at a cure, we were so grateful and wanted to give back,” said Sarah Asma, Executive Director, Big Nova, NMDP Foundation board member and $100 million campaign committee chair. “We are honored to continue to help more patients receive a second chance at life and help more families feel the same relief we did.”

Financial challenges are the No. 1 barrier patients cite to getting a blood stem cell transplant. Each day, NMDP receives 15 grant requests from patients needing help with transplant-related expenses like housing, transportation and medications. In 2025, NMDP provided more than $7 million in financial assistance to 3,405 patients.

Donor support is equally essential to NMDP’s mission. To ensure there is never a cost to donate, NMDP covers all travel expenses to donation centers for the donor and a companion, potential lost wages during donation and reimbursements for childcare, pet care or other needs during the approximately 40 hours committed over several weeks.

“Big Nova’s belief in our mission and their dedication to saving lives through cell therapy will have a lasting impact on thousands of patients and their families,” said Amy Ronneberg, CEO, NMDP. “Their support illustrates a family turning their loved one’s lifesaving experience into a powerful purpose: paying their gratitude forward to inspire hope and ensure that other patients have the same chance at a cure.”

In 2012, a young member of the Moore family received a blood stem cell transplant facilitated by NMDP. Since then, the Moore family has hosted recruitment drives, volunteered, and funded research, patient financial assistance, and recruitment programs.

Asma personally took on the role of campaign chair for NMDP’s $100 million comprehensive campaign launched in 2020 and the goal was recently met and surpassed. The Big Nova and Moore family’s gifts helped the organization achieve this historic fundraising milestone, which is critical to enabling more patients to access cell therapy.

The Moore family formed the Big Nova Foundation in 2023 to spark hope and ignite change among the causes near and dear to the family and the Central Florida community, which the family has called home for six generations.

Big Nova’s commitment reflects a deep connection to NMDP’s lifesaving work and vision of a world where every patient can receive their lifesaving cell therapy. Join this movement of hope and give a gift to support patients battling leukemia, lymphoma and other blood cancers or blood disorders by visiting: https://go.nmdp.org/BigNovaGive

About NMDP^SM
At NMDP^SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives.

CONTACT: Contact:
Erica Sevilla
NMDP
esevilla@nmdp.org

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12




Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.

A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available following the event.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Jenna Cohen
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13




MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026.

44^th Annual J.P. Morgan Healthcare Conference

Date: Tuesday, January 13, 2026
Format: Company presentation and 1×1 meetings
Time: 3:45 p.m. PT/ 6:45 p.m. ET
Location: San Francisco, California

The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device




NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device

• Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner
• Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia
• First commercial units to be delivered in March 2026

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) —  NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical, automotive and consumer electronics industries, with operations across Asia and partnerships around the globe. The investment was led by Checkmate Capital, a strategic advisory and investment group headquartered in Pasadena, California. The investment and manufacturing project are part of a collaboration between Armstrong and Checkmate, stemming from their July 2025 strategic memorandum of understanding (MOU) focused on the development and manufacturing of new technologies, particularly in the medical device industry.

“This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device,” said Colin Kealey, M.D., President and CEO of NeuroSigma. “As we move into 2026, we look forward to working with Armstrong Asia to deliver this innovative product to patients and families throughout the world.”

“We would like to thank NeuroSigma and Checkmate for selecting Armstrong as their manufacturing partner for the second-generation Monarch eTNS device,” added Phyllis Ong, CEO of Armstrong Asia. “Armstrong’s engineering team is highly inspired to co-design and manufacture advanced medical devices, and we look forward to producing the device at scale to serve the millions of patients suffering from ADHD.”

In November 2025, NeuroSigma announced successful completion of its pilot commercialization program for the first-generation Monarch eTNS device. During the pilot phase, the company dispensed over 1,000 Monarch devices and over 100,000 of the daily disposable patches. Based on strong market demand, NeuroSigma is preparing to launch the second-generation Monarch eTNS device in late Q1 2026.

“Completion of this investment marks a significant milestone for NeuroSigma, Armstrong, and Checkmate,” said Tom Paschall, CEO of Checkmate Capital and NeuroSigma Director. “Within the medical device industry, we see favorable conditions for the external neurostimulation sector and the central nervous system therapeutics market in general. The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”

Patients, families, and healthcare providers interested in the second-generation Monarch eTNS device and its upcoming launch can learn more at: http://www.monarch-etns.com.

About NeuroSigma
NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients’ lives. The company’s lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit www.neurosigma.com. For more information on the Monarch eTNS System, please visit www.monarch-etns.com.

About Armstrong Asia
Armstrong Asia is a precision engineering manufacturer established in Singapore since 1974, specializing in flexible material solutions for safer, better and greener innovations. With 16 factories and 2,600 employees across Malaysia, Thailand, Indonesia, Vietnam, Philippines and China, it strives to offer international customers with strategic footprint and trusted quality across Asia. Serving hundreds of global brand owners and OEMs, we understand the importance of consistently driving customer-centric innovation, optimizing supply chain and operational excellence, especially for the medical industry. Our technical partners around the globe are also invaluable to knowledge-sharing and speed of innovation. For more information, please visit www.armstrongasia.com.

Contact:
Colin Kealey, M.D., President of NeuroSigma at CKealey@neurosigma.com